U.S. Capital Markets Stock News

Raytech Holding Limited ( NASDAQ:RAY ) insiders who acquired shares over the previous 12 months, can probably afford to...

We wouldn't blame Aehr Test Systems, Inc. ( NASDAQ:AEHR ) shareholders if they were a little worried about the fact...

Aurinia Pharmaceuticals recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis patients, with complete renal response at 6 months as the primary endpoint. This post-approval trial builds on LUPKYNIS’s status as the only FDA-approved oral therapy for lupus nephritis and the only treatment to show a statistically significant increase in complete renal response at 6 months,...

GXO Logistics (GXO) stock is back in focus after the company renewed its long running partnership with Castorama for Moissy-Cramayel operations in France, reinforcing its role in the retailer’s nationwide supply chain. See our latest analysis for GXO Logistics. Against this backdrop, GXO Logistics’ recent 7 day share price return of 6.8% and 1 month share price return of 11.12% stand in contrast to a 3 month share price decline of 8.79% and a 3 year total shareholder return that is down...

BlackSky Technology (BKSY) is back in focus after securing several U.S. government research and development contracts for its Gen-3 AI constellation, which is centered on real-time space-based intelligence and battle damage assessment capabilities. See our latest analysis for BlackSky Technology. Despite the contract wins, BlackSky Technology’s 30 day share price return is down 23.46% and the 90 day share price return is down 40.70%. However, the 3 year total shareholder return is up 44.47%,...

Index reshuffle puts BrightSpring Health Services in focus BrightSpring Health Services (BTSG) moved from the S&P 600 to the S&P 400 Health Care index, a reshuffle that can change how index funds and institutional investors trade the stock. See our latest analysis for BrightSpring Health Services. BrightSpring Health Services has seen strong momentum build, with an 84.09% year to date share price return and a very large 254.42% 1 year total shareholder return. The latest index shift and...

United Fire Group stock has delivered a strong 141.1% return over the past 5 years, and after such a run the shares at around US$51 no longer look obviously cheap, especially with the broad valuation checks leaning toward a richer pricing. Over 5 years, United Fire Group has returned 141.1%. This puts extra weight on whether current investors are paying up for that past performance. Future growth in premiums and underwriting quality can support the current share price. Any pressure on claims...

With semiconductor stocks under pressure, oil prices and bond yields on the move, and inflation data easing the immediate threat of rate hikes, income investors are rethinking where to look for reliable cash flows. High dividend yield stocks can offer a steadier stream of returns when market sentiment swings from optimism to caution. This article uses a High Dividend Yield Stocks screener, filtered for companies with market caps over $100m and expected dividend yields of at least 3%, to...

Cathay General Bancorp stock has nearly doubled investors' money over the past five years, yet its Excess Returns intrinsic value estimate suggests the shares may still be pricing in a discount to what the business could be worth. At the same time, the broader valuation checks paint a more balanced picture rather than a straightforward bargain. Cathay General Bancorp has returned 98.3% over 5 years, which puts the current share price in the context of a strong longer term run for...

The EU’s move to ban the destruction of unsold clothes and footwear is forcing fashion groups to rethink how they plan, move, and clear inventory. Instead of quietly scrapping excess stock, brands may need better tools for forecasting demand, managing returns, and finding new resale or outlet channels. That shift puts the spotlight on supply chain and inventory technology providers that help retailers keep stock levels under tighter control. This article looks at 3 stocks that are directly...

MarketAxess Holdings has seen its share price fall sharply over the past five years, yet the current intrinsic value estimate from the Excess Returns model suggests the stock may trade at a sizable discount to its underlying worth. That gap, alongside a mixed overall value score, puts the focus squarely on whether the recent share price weakness has gone too far or is closer to fair. The stock is down 74.5% over the past five years, which puts long term holders deeply underwater and raises...

After Interactive Brokers Group stock delivered a very large 5 year total return of about 5.1x, the current checks point to a more cautious picture, with the Excess Returns intrinsic value estimate sitting close to the market price while earnings based multiples lean expensive. Over the past 5 years, Interactive Brokers Group has returned roughly 511.7%, which puts added pressure on today’s buyers to justify the valuation with future cash flows. Recent expansion of its electronic brokerage...

Nuclear energy developer X-Energy Inc. recently came under pressure as analysts adopted more cautious outlooks on reactor development progress and timelines, prompting broader scrutiny across the sector. An interesting angle is that, even as sentiment has cooled and expectations have become more measured, investors such as Ark Investment Management have been adding exposure, underscoring continued conviction in nuclear’s long-term role. Against this backdrop, we’ll explore how growing...

Ryder System, Inc. recently declared a regular quarterly cash dividend of US$1.01 per share, payable on September 18, 2026 to shareholders of record on August 24, 2026, marking an 11% or US$0.10 increase from the US$0.91 quarterly dividend initiated in July 2025. This higher payout suggests management is prioritizing direct cash returns to shareholders, which can be an important consideration for income-focused investors assessing Ryder’s overall appeal. We’ll now examine how Ryder’s 11%...

In July 2026, nLIGHT, Inc. announced it had been selected for a Joint Laser Weapon System Other Transaction Authority agreement supporting the U.S. Department of War’s next‑generation cruise missile defense architecture, with an initial US$44 million award and a total program ceiling of up to US$627 million including potential production options. The JLWS award reinforces nLIGHT’s role in high‑energy laser weapons, extending prior 50kW and 300kW program work into modular, containerized...

In the first half of 2026, iQIYI reported strong performance across dramas, variety shows, animation, micro dramas, and movies, with a majority of its long-form dramas earning top S+ ratings from third-party platform Enlightent and several titles achieving record popularity and high viewership shares. This breadth of high-impact content across multiple genres underscores how iQIYI’s programming slate is reinforcing its role as a premier streaming destination in China. We’ll now examine how...

China’s push to build an electric SUV that could beat Tesla’s Model Y on both price and technology puts Xpeng at the center of a fresh wave of competition, especially in Europe. With the new L03 SUV priced below the Model Y, European manufacturing expansion on the table, and autonomous driving software planned for 2027, the ripple effects stretch well beyond one company. This article looks at three stocks exposed to these catalysts, with two that could benefit and one that may face pressure,...

VinFast Auto recently reported that it delivered 17,955 electric vehicles in Vietnam in June 2026, bringing year‑to‑date domestic deliveries to 115,916 units, the first time any automaker has exceeded 100,000 vehicles in the first half of a calendar year in the country. Away from its home market, VinFast also launched a Certified Pre‑Owned program for its VF 8 and VF 9 SUVs across nine U.S. states, pairing rigorous vehicle inspections with up to 10 years of transferable warranty coverage to...

uniQure stock has delivered a very strong 301.7% return over the past three years, yet the current valuation checks lean expensive rather than cheap, which sets up a clear tension between past share price performance and what the numbers now suggest about value. The roughly fourfold return over three years signals that expectations around uniQure's future cash generation and execution have shifted materially, and the stock is now priced for meaningfully better outcomes than in the recent...

Hormone therapy is moving into the spotlight as the US military prepares to offer testosterone replacement therapy to eligible service members aged 30 and over, and that shift in policy could ripple through parts of the healthcare sector. For investors watching hormone-related therapies and pharmaceutical providers, this kind of institutional demand and political scrutiny can reshape expectations around future spending, regulation, and public debate. This article walks through 3 stocks from...

Forte Biosciences (FBRX) is back in focus after reporting statistically significant phase 1b data for FB102 in vitiligo, with early and sustained FVASI improvements and a safety profile that compared favorably to placebo. See our latest analysis for Forte Biosciences. Forte Biosciences has seen sharp positive momentum build around these FB102 results, with the 1 month share price return of 173.73% and year to date share price return of 106.95% contributing to a very large 1 year total...

ChronoScale Holdings shelf registration and ESOP related equity offering ChronoScale Holdings (CHRN) has filed a shelf registration for up to $452.016 million in equity shares, covering 25,800,000 securities tied to an Employee Stock Ownership Plan related offering. See our latest analysis for ChronoScale Holdings. ChronoScale Holdings has seen strong share price momentum alongside the shelf registration, with a 7 day share price return of 26.46%, a 90 day share price return of 132.25% and a...

Trevi Therapeutics recently reported that its oral extended-release nalbuphine candidate, Haduvio, produced a significant reduction in cough frequency in refractory chronic cough and idiopathic pulmonary fibrosis trials, and the company now plans to start a Phase 2b trial for non-IPF interstitial lung disease-related chronic cough in the second half of 2026. This progress highlights how a single late-stage asset is being positioned across several chronic cough populations where existing...

Chesapeake Financial Shares (CPKF) has just posted a punchy Q2 2026 update, with revenue of about US$26.4 million and basic EPS of US$1.75 alongside net income of roughly US$8.2 million. This puts fresh numbers behind the recent share price around US$37.78. Over the past few quarters the company has reported revenue of about US$19.3 million and EPS of US$0.67 in Q2 2025, US$21.7 million and US$1.37 in Q4 2025, and now US$26.4 million and US$1.75 in the current quarter. Over the same period,...